{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao J"],"funding":["Key research and development plan of Shaanxi province","National Natural Science Foundation of China","Xijing Hospital of the Fourth Military Medical University"],"pagination":["2276-2292"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9731625"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(12)"],"pubmed_abstract":["<h4>Background</h4>Gut dysbiosis is postulated to participate in the pathogenesis of IgA nephropathy (IgAN). However, the key bacterial taxa closely associated with IgAN onset and treatment response have not been identified.<h4>Methods</h4>We recruited 127 patients with IgAN who were treatment naive and 127 matched healthy controls (HCs) who were randomly divided into discovery and validation cohorts to investigate the characteristics of their gut microbiota and establish a bacterial diagnosis model for IgAN. A separate cohort of 56 patients and HCs was investigated to assess crossregional validation. A further 40 patients with primary membranous nephropathy (MN) were enrolled to probe disease-specific validation. A subgroup of 77 patients was prospectively followed to further dissect the "],"journal":["Journal of the American Society of Nephrology : JASN"],"pubmed_title":["Expansion of <i>Escherichia-Shigella</i> in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy."],"pmcid":["PMC9731625"],"funding_grant_id":["2017ZDXM-SF-045","82170722","81870470","XJZT18Z15"],"pubmed_authors":["Zhang Y","Sun S","Bai M","Ning X","Qin Y","Wang Y","Yu Z","Zhao J","Dong R"],"additional_accession":[]},"is_claimable":false,"name":"Expansion of <i>Escherichia-Shigella</i> in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy.","description":"<h4>Background</h4>Gut dysbiosis is postulated to participate in the pathogenesis of IgA nephropathy (IgAN). However, the key bacterial taxa closely associated with IgAN onset and treatment response have not been identified.<h4>Methods</h4>We recruited 127 patients with IgAN who were treatment naive and 127 matched healthy controls (HCs) who were randomly divided into discovery and validation cohorts to investigate the characteristics of their gut microbiota and establish a bacterial diagnosis model for IgAN. A separate cohort of 56 patients and HCs was investigated to assess crossregional validation. A further 40 patients with primary membranous nephropathy (MN) were enrolled to probe disease-specific validation. A subgroup of 77 patients was prospectively followed to further dissect the ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-21T23:06:43.267Z","creation":"2025-04-05T19:04:03.727Z"},"accession":"S-EPMC9731625","cross_references":{"pubmed":["36041791"],"doi":["10.1681/ASN.2022020189","10.1681/asn.2022020189"]}}